• Pierre Van Damme, Paolo Bonanni, F Xavier Bosch, Elmar Joura, Susanne Krüger Kjaer, Chris J L M Meijer, Karl-Ulrich Petry, Benoit Soubeyrand, Thomas Verstraeten, and Margaret Stanley.
• Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium. Electronic address: pierre.vandamme@uantwerp.be.
• Vaccine. 2016 Feb 3; 34 (6): 757-61.

AbstractWith the availability of the nonavalent human papillomavirus (HPV) vaccine, vaccinees, parents and healthcare providers need guidance on how to complete an immunization course started with the bi- or quadrivalent vaccine and whether to revaccinate individuals who have completed a full immunization course with the bi- or quadrivalent vaccine. To answer these questions three parameters should be considered: age at the start of vaccination (9 to 14 years of age versus 15 years and older, the cut-off for 2 or 3 doses schedule), the number of doses already received and the time interval between doses. Based on a number of scenarios, we propose that the 9-valent vaccine can be used to complete an incomplete vaccination regimen or might be added to a previous completed schedule to extend protection. Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

16 keywords...

hide…